Accessibility Menu
Monopar Therapeutics logo

Monopar Therapeutics(NASDAQ) MNPR

Market Cap$739.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-17%
5 Year+316%
1 Year+145%
1 Month+26%
$108.27
-1.87%
-2.06Today
Monopar Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 110.332026-07-27
Monopar Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.18%USD 105.902026-07-20
1 month+25.83%USD 87.682026-06-26
3 month+102.51%USD 54.482026-04-28
Year to date+68.96%USD 65.302025-12-31
1 year+145.34%USD 44.972025-07-25
3 year+2,910.37%USD 3.672023-07-28
5 year+316.34%USD 26.502021-07-28
Since inception-16.73%USD 132.502019-12-19

Monopar Therapeutics Financials at a Glance

Market Cap

$739.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$14.98M

EPS (TTM)

-$2.07

P/E Ratio

-53.39

Dividend

$0.00

Beta (Volatility)

0.66 (Low)

Price

$108.27

Volume

19,043

Open

$109.14

Previous Close

$108.27

Daily Range

$105.07 - $110.12

52-Week Range

$29.18 - $116.64

Estimated Earnings Date

Aug 11, 2026

MNPR News

No articles available.

MNPR: Motley Fool Moneyball Superscore

54

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Monopar Therapeutics

Monopar develops medicines for cancer and rare diseases. Its main drugs aim to help patients facing tough treatments or limited options. The company focuses on therapies that could ease side effects or target hard-to-treat cancers.

Lab Bench to Bedside: What Monopar Makes

  • ALXN1840 (tiomolybdate choline): Oral drug in late-stage testing for Wilson disease, a rare genetic disorder; 0% of revenue as of June 2025.
  • Radiopharmaceuticals: Imaging and treatment agents (MNPR-101-Zr, MNPR-101-Lu, MNPR-101-Ac) for advanced cancers; 0% of revenue as of June 2025.
  • Camsirubicin: Chemotherapy analog in early trials for soft tissue sarcoma, a rare cancer; 0% of revenue as of June 2025.
  • MNPR-202: Drug candidate for cancers resistant to standard treatments; 0% of revenue as of June 2025.

Growth Spurts and Science Sprints

  • Acquired exclusive global rights to ALXN1840 from Alexion in October 2024.
  • Launched Phase 1 trials for MNPR-101-Zr (April 2024) and MNPR-101-Lu (October 2024).
  • Secured long-term radioisotope supply deal with NorthStar Medical Radioisotopes in 2024.
  • Partnered with Grupo Español de Investigación en Sarcomas and Cancer Science Institute of Singapore for drug development.
  • Expanded access programs for radiopharmaceuticals approved by FDA in June 2025.

Why Monopar Is a Bit Different

Monopar focuses on rare diseases and aggressive cancers, using both in-house research and licensed drugs. Its radiopharmaceuticals use a unique antibody to target cancer cells. The company relies on partnerships for research, supply, and clinical trials.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Net loss was $2.45 million in Q2 2025, up 43.1% from Q2 2024.
  • Cash and investments totaled $53.3 million as of June 30, 2025.
  • Operating expenses were $3.23 million in Q2 2025, up 80.8% year-over-year.
  • No debt or credit facilities as of June 2025; all funding from equity and investments.

Bottom Line

Monopar remains a research-focused biotech with no product sales and ongoing clinical trials. Its future depends on advancing drug candidates and securing funding for continued development.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

22

CEO

Chandler Drew Robinson, MD, MBA

Website

www.monopartx.com

Headquarters

Wilmette, IL 60091, US

MNPR Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-12.84%

Return on Capital

-12.11%

Return on Assets

-10.86%

Earnings Yield

-1.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$739.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.70M

Volume

19.04K

Avg. Volume

189.19K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$18.71M

EBITDA

-$15.64M

Operating Cash Flow

-$10.01M

Capital Expenditure

-$3.00

Free Cash Flow

-$10.01M

Cash & ST Invst.

$137.49M

Total Debt

$131.57K

Monopar Therapeutics Performance Analysis

Monopar Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Monopar Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Monopar Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.1313.3%
20232023-12-31USD -3.04-26.5%
20242024-12-31USD -4.1135.3%
20252025-12-31USD -1.85-55.0%
Monopar Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-307.9%
Q32025-09-30-37.1%
Q42025-12-31-62.5%
Q12026-03-3141.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$739.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$33.60M

N/A

Employees

22

N/A

Net Income

-$3.89M

-48.3%

EBITDA

-$3.89M

-48.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$137.49M

+152.0%

Total Debt

$131.57K

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$131.57K

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-10.86%

N/A

Return on Invested Capital

-13.80%

N/A

Free Cash Flow

-$3.47M

+38.7%

Operating Cash Flow

-$3.47M

+38.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OMEROmeros Corporation
$11.28-0.53%
FDMT4D Molecular Therapeutics, Inc.
$9.85-5.11%
LXRXLexicon Pharmaceuticals, Inc.
$2.34+4.93%
CMPXCompass Therapeutics, Inc.
$2.04-1.92%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.22-0.01%
NOKNokia
$8.93-0.03%
JBLUJetBlue Airways
$6.00+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.15-0.01%

Questions About MNPR

What is the current price of Monopar Therapeutics?

Monopar Therapeutics is trading at $108.27 per share.

What is the 52-week range for Monopar Therapeutics?

Over the past 52 weeks, Monopar Therapeutics has traded between $29.18 and $116.64.

How much debt does Monopar Therapeutics have?

As of the most recent reporting period, Monopar Therapeutics reported total debt of $131.57K.

How much cash does Monopar Therapeutics have on hand?

Monopar Therapeutics reported $52.54M in cash and cash equivalents in its most recent financial results.

What is Monopar Therapeutics’s dividend yield?

Monopar Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services